In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: Haematoprotection acts as a drug-specific progenitor rescue

British Journal of Cancer

Volumn 78, Issue 8, 1998, Pages 1024-1029

  Pierelli, L ^a   Scambia, G ^a   Fattorossi, A ^a   Bonanno, G ^a   Battaglia, A ^a   Perillo, A ^a   Menichella, G ^a   Benedetti Panici, P ^a   Leone, G ^a   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Amifostine; Carboplatin and non alkylating drugs; Haematoprotection in vitro

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CD34 ANTIGEN; DOCETAXEL; ETOPOSIDE;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOSIS; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 7344224953     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.622     Document Type: Article

References (30)

1. Bartkowiak D, Hemmer J and Rottinger E (1992) Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro. Cancer Chemother Pharmacol 30: 189-192
2. Betticher DC, Anderson H, Ranson M, Meely K, Oster W and Thatcher H (1995) Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer: a randomized phase III study. Br J Cancer 72: 1551-1555
3. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick A, Wilson P, Auzannet V, Le Bail N, Kaye SB and Kerr DJ (1993) Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523-527
4. Calabro-Jones PM, Fahey RC, Smoluk GD and Ward JF (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47: 23-27
5. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk JD and Fahey RC (1988) Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634-3640
6. Chaudhary PM and Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94
7. Darzinkyewich Z, Juan G, Li X, Gorczyca W, Murakami T and Traganos F (1997) Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27: 1-20
8. De Vincenzo R, Scambia G, Benedetti Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S and Mancuso S (1996) Modulatory effect of tamoxifen and ICI 182,780 on adryamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 68: 340-348
9. Douay L, Hu C, Giarratana M-C, Bouchet S, Conlon J, Capizzi RL and Gorin N-C (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86: 2849-2855
10. Ferlini C, Biselli R, Nisini R and Fattorossi A (1995) Rhodamine 123: a useful probe to monitoring T cell activation. Cytometry 21: 284-292
11. Glover DJ, Glick JH, Weiler C, Hurowitz S and Kligerman MM (1986) WR-2721 protect against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 4: 584-588
12. Issels RD and Nagele A (1989) Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res 49: 2082-2086
13. Kemp G, Rose P, Lurain J, Berman H, Mahetta A, Roullet B, Hamesley H, Belpomme D and Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide and cisplatin-induced toxicities: results of a randomized controlled trials in patients with advanced ovarian cancers. J Clin Oncol 14: 2101-2112
14. List AF, Heaton R, Glinsman-Gibson B and Capizzi RL (1996) Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23: 58-63
15. Lyons AB and Christopher RP (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171: 131-137
16. Meier T and Issels RD (1995) Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of chinese hamster ovary cells. Biochem Pharmacol 50: 489-496
17. Menichella G, Pierelli L, Scambia G, Salerno G, Benedetti Panici P, Foddai ML, Serafini R, Puglia G, Lai M, Ciarli M, Mancuso S and Bizzi B (1994) Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplant 14: 907-912
18. Muindi J, Sinha BK, Giunni L and Myers C (1985) Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms. Mol Pharmacol 27: 356-365
19. Ohnishi ST, Ohnishi T and Glick JH (1992) In vitro study on the antioxidant activities of amifostine (WR-2721) (abstract). Proc Am Assoc Cancer Res 33: 419
20. Pierelli L, Menichella G, Paoloni A, Vittori M, Foddai ML, Serafini R, Rumi C, Mitschulat H, Rossi PL, Scambia G, Teollli L, Sica S, Leone G and Bizzi B (1993) Evaluation of a novel automated protocol for the collection of peripheral blood stem cells mobilized with chemotherapy or chemotherapy plus G-CSF using the Fresenius AS104 cell separator. J Hematother 2: 145-153
21. Pierelli L, Scambia G, Menichella G, Fattorossi A, Ciarli M, Bonanno G, Battaglia A, d'Onofrio G, Benedetti Panici P, Iacone A, Mancuso S and Leone G (1997) Purified unfractionated G-CSF/chemotherapy mobilized CD34+ peripheral blood progenitors and not bone marrow CD34+ progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. Br J Haematol 96: 55-63
22. Purdie JW and Inhaber ER (1983) Interaction of cultured mammalian cells with WR-2721 and its thiol WR-1065: implications for mechanism of radioprotection. Int J Radiat Biol 43: 517-527
23. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast Jr RC, McCulloch W, Capizzi R, Mitchell E, Schein PS and Jones RB (1994) Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132-3137
24. Treskes M and van der Vijgh WJ (1993) WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agaents: a molecular approach. Cancer Chemother Pharmacol 33: 93-106
25. Wasserman TH, Phillips TL, Ross G and Kane LJ (1981) Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4: 3-6
26. Willson RL (1983) Free radical repair mechanisms and interaction of glutathione and vitamins C and E. In Radioprotectors and Anticarcinogenesis. Nygaard OF and Simic MG (eds), pp. 1-22. Academic Press: New York
27. Yuhas JM (1969) Differential protection of normal and malignant tissues against the cytotoxic effects of mechloretamine. Cancer Treat Rep 63: 971-976
28. Yuhas JM and Storer JB (1969) Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42: 331-335
29. Yuhas JM, Spellman JM and Culo F (1980a) The role of WR-2721 in radiotherapy and/or chemotherapy. In Radiation Sensitizer. Brady L (ed.), pp. 303-308. Masson: New York
30. Yuhas JM, Spellman JM and Jordan SW (1980b) Treatment of tumours with the combination of Amifostine and Cis-Dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42: 574-585